13F Pro Quality Score

31.9/100

Rank #2,444 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

33.9/100

Profitability

25.2/100

Balance Sheet

18.8/100

Earnings Quality

45.8/100

Free Cash Flow

24.3/100

Institutional Flow

50.1/100

Revenue Scale

32.3/100

Dilution Risk

37.7/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

INGN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Inogen Inc (INGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INGN at 31.9/100 on a 32-signal composite quality model, placing it at rank #2,444 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (18.8) and free cash flow (24.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Inogen Inc reports quarterly revenue of $95.1M, net income of $-3.9M, an operating margin of -5.4%. Top institutional holders of INGN by reported 13-F value include BlackRock, ARMISTICE CAPITAL, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. INGN trades on the Nasdaq exchange and files with the SEC under CIK 1294133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inogen Inc directly from SEC EDGAR. Inogen Inc's 13F Pro composite quality score has ranged between 19 and 44 since 2021, currently 31.9 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

Fun facts about Inogen Inc

Quirks, history, and lore behind INGN — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. medical device company · small-cap · listed on Nasdaq · headquartered in California.
  • 2
    The Numbers
    Annual revenue in the range of $300–400 million — modest by pharma standards, but it dominates a niche where patients literally can't breathe without it.
  • 3
    The History
    Founded in the early 2000s, it set out to solve a very specific frustration: why should patients needing supplemental oxygen be chained to a wall-mounted tank?
  • 4
    The Secret
    Its core innovation is a portable oxygen concentrator — a device that pulls oxygen straight from ambient air, eliminating the need for heavy compressed-gas cylinders entirely.
  • 5
    The Lore
    It sells directly to COPD and respiratory patients and also rents units through Medicare reimbursement — meaning grandma can take a stroll in the park without a cart of tanks in tow.
  • 6
    The Giveaway
    Its name is a portmanteau of "innovative" and "oxygen," and its flagship devices let chronic lung patients travel by plane, hike, and live untethered for the first time.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$95.1M

Net Income

Q2 2026

$-3.9M

Free Cash Flow

Q2 2026

$2.2M

Operating Margin

Q2 2026

-5.4%

ROIC

Q2 2026

-11.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+3.9% YoY
$348.7MFY 2025
FY22 $377.2MFY23 $315.7MFY24 $335.7MFY25 $348.7M

Net Income

+36.6% YoY
$-22.7MFY 2025
FY22 $-83.8MFY23 $-102.4MFY24 $-35.9MFY25 $-22.7M

Operating Income

+29.0% YoY
$-30.2MFY 2025
FY22 $-85.2MFY23 $-109.4MFY24 $-42.5MFY25 $-30.2M

EPS (Diluted)

+43.4% YoY
$-0.86FY 2025
FY22 $-3.67FY23 $-4.42FY24 $-1.52FY25 $-0.86

Total Assets

+0.8% YoY
$298.6MFY 2025
FY22 $405.0MFY23 $326.2MFY24 $296.2MFY25 $298.6M

Op. Cash Flow

-289.7% YoY
$-11.2MFY 2025
FY22 $-37.5MFY23 $-3.2MFY24 $5.9MFY25 $-11.2M

Free Cash Flow

-637.9% YoY
$-13.7MFY 2025
FY22 $-40.9MFY23 $-8.5MFY24 $2.6MFY25 $-13.7M

Get alerted when INGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inogen Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Companies Similar to INGN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

OFIX

Orthofix Medical Inc.

35
AI score
Similar quality profile · 4 shared holders
VNDA

Vanda Pharmaceuticals Inc.

24
AI score
Similar quality profile · 2 shared holders
ANGO

ANGIODYNAMICS INC

30
AI score
Similar quality profile · 3 shared holders
DCGO

DocGo Inc.

17
AI score
Similar quality profile · 4 shared holders
OSUR

ORASURE TECHNOLOGIES INC

13
AI score
Similar quality profile · 4 shared holders
ORGO

Organogenesis Holdings Inc.

30
AI score
Similar quality profile · 3 shared holders
NPCE

NeuroPace Inc

31
AI score
Similar quality profile · 2 shared holders
TNDM

TANDEM DIABETES CARE INC

40
AI score
Similar quality profile · 3 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put INGN on your watchlist

Track score changes the day Inogen Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is INGN a good stock to buy?

13F Pro's AI-powered analysis of Inogen Inc (INGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INGN are available on the INGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INGN is classified as a small company.

Which hedge funds own INGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inogen Inc's investment landscape.